NuCana is a biotechnology business based in the US. NuCana shares (NCNA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.14 – an increase of 0.88% over the previous week. NuCana employs 25 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.14 |
|---|---|
| 52-week range | $0.96 - $11.00 |
| 50-day moving average | $1.33 |
| 200-day moving average | $3.05 |
| Wall St. target price | $64.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-14.35 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.14 from 2025-01-17
| 1 week (2025-01-10) | 0.88% |
|---|---|
| 1 month (2024-12-20) | -5.79% |
| 3 months (2024-10-18) | -39.36% |
| 6 months (2024-07-19) | -61.74% |
| 1 year (2024-01-19) | 280.25% |
|---|---|
| 2 years (2023-01-18) | -96.96% |
| 3 years (2022-01-19) | 67.5 |
| 5 years (2020-01-17) | 142 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -68.43% |
| Return on equity TTM | -180.77% |
| Profit margin | 0% |
| Book value | $7.11 |
| Market Capitalization | $4.2 million |
TTM: trailing 12 months
We're not expecting NuCana to pay a dividend over the next 12 months.
NuCana's shares were split on a 1:25 basis on 15 April 2024 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NuCana shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for NuCana shares which in turn could have impacted NuCana's share price.
Over the last 12 months, NuCana's shares have ranged in value from as little as $0.9601 up to $10.9998. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NuCana's is 1.038. This would suggest that NuCana's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Find out more about this component of your brokerage account and how you can use this cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.